Implementing Pharmacogenetic Testing in Gastrointestinal Cancers

Exclusion Criteria

• •1. Prior treatment with irinotecan
• •2. DPYD or UGT1A1 genotype already known
• •3. Severe renal or hepatic impairment (or unacceptable laboratory values), including:
• •* Neutrophil count of \<1.5 x 109/L, platelet count of \<100 x 109/L
• •* Hepatic function as defined by serum bilirubin \>1.5 x upper limit of normal (ULN), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) \>2.5 x ULN, or in case of liver metastases ALT and AST\>5 x ULN
• •* Renal function as defined by serum creatinine \>1.5 x ULN, or creatinine clearance \<60 ml/min (by Cockcroft-Gault Equation)
• •4. Women who are pregnant or breast feeding, or subjects who refuse to use reliable contraceptive methods throughout the study
• •5. Treating physician does not want subject to participate